Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk.
Objective:
To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS).
Methods:
The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal.
Results:
Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations.
Conclusion:
These recommendations propose a strategic approach to managing cancer risk in PwMS.
MarrieRAYuNBlanchardJ, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology2010; 74: 465–471.
3.
SolaroCPonzioMMoranE, et al. The changing face of multiple sclerosis: Prevalence and incidence in an aging population. Mult Scler2015; 21: 1244–1250.
4.
MarrieRAFiskJDFitzgeraldK, et al. Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances. Front Immunol2023; 14: 1197195.
5.
CorboyJRFoxRJKisterI, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): A multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol2023; 22: 568–577.
6.
VukusicSCarra-DalliereCCironJ, et al. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler2023; 29: 11–36.
7.
DonzéCPapeixCLebrun-FrenayC, et al. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris)2020; 176(10): 804–822.
8.
LebrunCVukusicS; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord2019; 31: 173–188.
9.
PapeixCDonzeCLebrun-FrenayC, et al. Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris)2021; 177: 980–994.
10.
RAND Corporation. The RAND/UCLA appropriateness method user’s manual. Santa Monica, CA: RAND Corporation, 2001.
GhajarzadehMMohammadiASahraianMA. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis. Autoimmun Rev2020; 19: 102650.
13.
HandelAERamagopalanSV. Multiple sclerosis and risk of cancer: A meta-analysis. J Neurol Neurosurg Psychiatry2010; 81: 1413–1414.
14.
HauerLPerneczkyJSellnerJ. A global view of comorbidity in multiple sclerosis: A systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol2021; 268: 4066–4077.
15.
MagyariMSorensenPS. Comorbidity in multiple sclerosis. Front Neurol2020; 11: 851.
16.
MarrieRAReiderNCohenJ, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler2015; 21: 294–304.
17.
MarrieRAMaxwellCMaharA, et al. Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study. Neurology2021; 96: e501–e512.
18.
AchironABarakYGailM, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat2005; 89: 265–270.
19.
BahmanyarSMontgomerySMHillertJ, et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology2009; 72: 1170–1177.
20.
Bosco-LévyPFochCGrelaudA, et al. Incidence and risk of cancer among multiple sclerosis patients: A matched population-based cohort study. Eur J Neurol2022; 29: 1091–1099.
21.
D’AmicoEChisariCGArenaS, et al. Cancer risk and multiple sclerosis: Evidence from a large Italian cohort. Front Neurol2019; 10: 337.
22.
EtemadifarMJahanbani-ArdakaniHGhaffariS, et al. Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. Caspian J Intern Med2017; 8: 172–177.
23.
GaindhDKavakKSTeterB, et al. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. J Neurol Sci2016; 370: 13–17.
24.
GryttenNMyhrKMCeliusEG, et al. Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Mult Scler Relat Disord2021; 55: 103209.
25.
HongellKKurkiSSumelahtiML, et al. Risk of cancer among Finnish multiple sclerosis patients. Mult Scler Relat Disord2019; 35: 221–227.
26.
KingwellEBajdikCPhillipsN, et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain2012; 135: 2973–2979.
27.
KuiperJGOverbeekJAFochC, et al. Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network. J Clin Neurosci2022; 103: 49–55.
28.
NørgaardMVeresKDiddenEM, et al. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord2019; 28: 81–85.
29.
SunLMLinCLChungCJ, et al. Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. Eur J Neurol2014; 21: 238–244.
30.
ZeccaCDisantoGSaccoR, et al. Increasing cancer risk over calendar year in people with multiple sclerosis: A case-control study. J Neurol2021; 268: 817–824.
31.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376: 209–220.
32.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376: 221–234.
33.
HajiebrahimiMMontgomerySBurkillS, et al. Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients. PLoS ONE2016; 11: e0165027.
34.
GryttenNMyhrKMCeliusEG, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Mult Scler2020; 26: 1569–1580.
35.
FoisAFWottonCJYeatesD, et al. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: Record linkage studies. J Neurol Neurosurg Psychiatry2010; 81: 215–221.
36.
MidgardRGlattreEGrønningM, et al. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand1996; 93: 411–415.
37.
NielsenNMRostgaardKRasmussenS, et al. Cancer risk among patients with multiple sclerosis: A population-based register study. Int J Cancer2006; 118: 979–984.
38.
SumelahtiMLPukkalaEHakamaM. Cancer incidence in multiple sclerosis: A 35-year follow-up. Neuroepidemiology2004; 23: 224–227.
39.
LebrunCDebouverieMVermerschP, et al. [CARIMS (cancer risk in multiple sclerosis) project: Impact of long-term treatment]. Rev Neurol (Paris)2007; 163: 38–46.
40.
BigautKCohenMDurand-DubiefF, et al. How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Mult Scler Relat Disord2021; 53: 103076.
41.
DolladilleCChrétienBPeyro-Saint-PaulL, et al. Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: A WHO pharmacovigilance database analysis. Neurotherapeutics2021; 18: 1657–1664.
42.
LebrunCVermerschPBrassatD, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol2011; 258: 1304–1311.
43.
Sandberg-WollheimMKornmannGBischofD, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: Analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler2011; 17: 431–440.
44.
KingwellEEvansCZhuF, et al. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry2014; 85: 1096–1102.
45.
BloomgrenGSperlingBCushingK, et al. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: Retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manag2012; 8: 313–321.
46.
ConfavreuxCO’ConnorPComiG, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13: 247–256.
47.
O’ConnorPWolinskyJSConfavreuxC, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365: 1293–1303.
48.
LebrunCRocherF. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. CNS Drugs2018; 32: 939–949.
49.
LandaisAAlhendiRGouverneurA, et al. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis. Mult Scler Relat Disord2017; 17: 92–94.
50.
StamatellosVPSiafisSPapazisisG. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration adverse event reporting system database. Br J Clin Pharmacol2021; 87: 4769–4779.
51.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
52.
GoldRKapposLArnoldDL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367: 1098–1107.
53.
HavrdovaEHutchinsonMKurukulasuriyaNC, et al. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: A review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother2013; 14: 2145–2156.
54.
Gómez-MorenoMSánchez-SecoVGMoreno-GarcíaS, et al. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. Mult Scler Relat Disord2021; 49: 102747.
55.
Gil-BernalRGonzalez-CaballeroJLEspinosa-RossoR, et al. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients. Sci Rep2021; 11: 12533.
56.
XieXZhaoYMaCY, et al. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway. Br J Pharmacol2015; 172: 3929–3943.
57.
CalabresiPARadueEWGoodinD, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13: 545–556.
58.
KillesteinJLeursCEHoogervorstELJ, et al. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology2017; 89: 970–972.
59.
CohenJAKhatriBBarkhofF, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry2016; 87: 468–475.
60.
StamatellosVPRigasAStamoulaE, et al. S1P receptor modulators in multiple sclerosis: Detecting a potential skin cancer safety signal. Mult Scler Relat Disord2022; 59: 103681.
61.
AlpingPAsklingJBurmanJ, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol2020; 87: 688–699.
62.
MahajanKRKoJSTetzlaffMT, et al. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report. Mult Scler Relat Disord2017; 17: 12–14.
63.
PapathemeliDGräfeRHildebrandtU, et al. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler2016; 22: 1888–1890.
64.
CohanSGodwinJGaedekeL. Acute lymphoblastic leukemia in a man treated with fingolimod for relapsing multiple sclerosis. J Investig Med High Impact Case Rep2015; 3(1): 2324709615575551.
65.
SamaraweeraAPCohenSNAkayEM, et al. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Mult Scler2016; 22: 122–124.
66.
WalkerSBrewB. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis. J Clin Neurosci2016; 31: 217–218.
67.
Ruetsch-ChelliCOkudaDTRocherF, et al. Sphingosine-1 phosphate receptor modulators increase in vitro melanoma cell line proliferation at therapeutic doses used in patients with multiple sclerosis. Neurol Ther2023; 12: 289–302.
68.
TriplettJKermodeAGCorbettA, et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler2019; 25: 1547–1550.
69.
MhannaENouchiALouapreC, et al. Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination. Mult Scler2021; 27: 1794–1798.
70.
OcalanM-DMorkavukGGursoyA-Y, et al. HPV-associated anal and genital intraepithelial neoplasia after using fingolimod in the treatment of relapsing-remitting multiple sclerosis: A case report. J Mult Scler Res2022; 2: 28–30.
71.
BenedettiMDMarangiABozzettiS, et al. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult Scler Relat Disord2018; 23: 24–26.
72.
KapposLBar-OrACreeBAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet2018; 391: 1263–1273.
73.
CreeBAArnoldDLFoxRJ, et al. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Mult Scler2022; 28: 1591–1605.
74.
ComiGKapposLSelmajKW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol2019; 18: 1009–1020.
75.
CohenJAComiGSelmajKW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019; 18: 1021–1033.
76.
CreeBASelmajKWSteinmanL, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler2022; 28: 1944–1962.
77.
KapposLFoxRJBurcklenM, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial. JAMA Neurol2021; 78: 558–567.
78.
MillerDHKhanOASheremataWA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
79.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
80.
ButzkuevenHKapposLWiendlH, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry2020; 91: 660–668.
81.
FoleyJCarrillo-InfanteCSmithJ, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord2019; 39: 101863.
82.
IsmailAKempJSharrackB. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol2009; 256: 1771–1772.
83.
LaroniABedognettiMUccelliA, et al. Association of melanoma and natalizumab therapy in the Italian MS population: A second case report. Neurol Sci2011; 32: 181–182.
84.
MullenJTVartanianTKAtkinsMB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med2008; 358: 647–648.
85.
SabolRANoxonVSartorO, et al. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med2017; 6: 1541–1551.
86.
HauserSLKapposLMontalbanX, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology2021; 97: e1546–e1559.
87.
van VollenhovenRFEmeryPBinghamCOIII, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis2013; 72: 1496–1502.
88.
WadstromHFrisellTAsklingJ, et al. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden. JAMA Intern Med2017; 177: 1605–1612.
89.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383: 546–557.
90.
Bar-OrAGroveRAAustinDJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology2018; 90: e1805–e1814.
91.
FoxELovett-RackeAEGormleyM, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler2021; 27: 420–429.
92.
SteinmanLFoxEHartungHP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med2022; 387: 704–714.
93.
CohenJAColesAJArnoldDL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
94.
ColesAJCohenJAFoxEJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology2017; 89: 1117–1126.
95.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
96.
MartinelliVCoccoECapraR, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology2011; 77: 1887–1895.
97.
HasanSKButtariFOttoneT, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: Coding variants of DNA repair genes. Neurology2011; 76: 1059–1065.
98.
ButtmannMSeuffertLMaderU, et al. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology2016; 86: 2203–2207.
99.
ChartierNEpsteinJSoudantM, et al. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: A real-life cohort study. Eur J Neurol2018; 25: 1439–1445.
100.
GiovannoniGComiGCookS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–426.
101.
PakpoorJDisantoGAltmannDR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm2015; 2: e158.
102.
LeistTCookSComiG, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord2020; 46: 102572.
103.
HarwoodCAAttardNRO’DonovanP, et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer2008; 99: 1276–1284.
104.
Peyrin-BirouletLKhosrotehraniKCarratF, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology2011; 141: 1621–1628. e1–e5.
105.
Gutierrez-DalmauACampistolJM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs2007; 67: 1167–1198.
ConfavreuxCSaddierPGrimaudJ, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology1996; 46: 1607–1612.
108.
La MantiaLBenedettiMDSantM, et al. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: An Italian observational study. Neurol Sci2021; 42: 5157–5163.
109.
TaylorLHughesRAMcPhersonK. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol2004; 11: 141.
110.
EisenHJKobashigawaJKeoghA, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant2005; 24: 517–525.
111.
WangKZhangHLiY, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: A systematic review. Transplant Proc2004; 36: 2068–2070.
112.
HirunsatitpronPHanprasertpongNNoppakunK, et al. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. Br J Clin Pharmacol2022; 88: 476–489.
113.
BalciMAPamukGEUnluE, et al. Development of primary central nervous system lymphoma in a systemic lupus erythematosus patient after treatment with mycophenolate mofetil and review of the literature. Lupus2017; 26: 1224–1227.
114.
DasguptaNGelberACRackeF, et al. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus2005; 14: 910–913.
115.
FinelliPFNaikKDiGiuseppeJA, et al. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus2006; 15: 886–888.
116.
O’NeillBPVerninoSDoganA, et al. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol2007; 9: 364–369.
117.
SakairiTNakasatomiMWatanabeM, et al. Primary central nervous system lymphoma in a patient with neuropsychiatric systemic lupus erythematosus receiving mycophenolate mofetil: A case report and literature review. Mod Rheumatol Case Rep2022; 6: 36–40.
118.
TsangHHTrendell-SmithNJWuAK, et al. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus2010; 19: 330–333.
119.
NyforsAJensenH. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. Dermatologica1983; 167: 260–261.
120.
HashimotoAChibaNTsunoH, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol2015; 42: 564–571.
121.
HellgrenKBaecklundEBacklinC, et al. Rheumatoid arthritis and risk of malignant lymphoma: Is the risk still increased?Arthritis Rheumatol2017; 69: 700–708.
122.
StarkJWJosephsLDulakD, et al. Safety of long-term intrathecal methotrexate in progressive forms of MS. Ther Adv Neurol Disord2019; 12: 1756286419892360.
123.
KamedaTDobashiHMiyatakeN, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken)2014; 66: 1302–1309.
124.
InoseRHosomiKTakahashiK, et al. Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate. Int J Clin Pharmacol Ther2019; 57: 63–72.
125.
De RidderDvan PoppelHDemontyL, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol1998; 159: 1881–1884.
126.
FaurschouMSorensenIJMellemkjaerL, et al. Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol2008; 35: 100–105.
127.
Talar-WilliamsCHijaziYMWaltherMM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med1996; 124: 477–484.
128.
Le BoucRZéphirHMajedB, et al. No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. Mult Scler2012; 18: 55–63.
129.
PortaccioEZipoliVSiracusaG, et al. Safety and tolerability of cyclophosphamide “pulses” in multiple sclerosis: A prospective study in a clinical cohort. Mult Scler2003; 9: 446–450.
130.
RagonesePAridonPVazzolerG, et al. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: A cohort study. BMC Neurol2017; 17: 155.
131.
EmadiAJonesRJBrodskyRA. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol2009; 6: 638–647.
132.
RadisCDKahlLEBakerGL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum1995; 38: 1120–1127.
133.
DeGeorgeKCHoltHRHodgesSC. Bladder cancer: Diagnosis and treatment. Am Fam Physician2017; 96: 507–514.
134.
BilmonIAAshtonLJLe MarsneyRE, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study. Bone Marrow Transplant2014; 49: 691–698.
135.
BurtRKBalabanovRBurmanJ, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs. continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA2019; 321: 165–174.
LiCGYangLShengJQ. Hereditary colorectal cancer in China: Current status and progress. Gastrointestinal Tumors2015; 2: 98–108.
138.
ChatawayJFeakesRCoradduF, et al. The genetics of multiple sclerosis: Principles, background and updated results of the United Kingdom systematic genome screen. Brain1998; 121(Pt. 10): 1869–1887.
139.
GoodinDSKhankhanianPGourraudPA, et al. The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS ONE2021; 16(3): e0246157.
140.
KormanAJGarrett-ThomsonSCLonbergN. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov2022; 21: 509–528.
141.
HemminkiKLiuXJiJ, et al. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol2012; 127(1): 180–185.
142.
MorettaJBerthetPBonadonaV, et al. Recommandations françaises du Groupe Génétique et Cancer pour l’analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l’ovaire. Bull Cancer2018; 105: 907–917.
143.
StroetAHemmelmannCStarckM, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord2012; 5: 75–79.
144.
El-NachefLAl-ChoboqJRestier-VerletJ, et al. Human radiosensitivity and radiosusceptibility: What are the differences?Int J Mol Sci2021; 22: 7158.
145.
CuzzubboSJaveriFTissierM, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer2017; 73: 1–8.
146.
Abdel-WahabNShahMLopez-OlivoMA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med2018; 169: 133–134.
147.
YshiiLMHohlfeldRLiblauRS. Inflammatory CNS disease caused by immune checkpoint inhibitors: Status and perspectives. Nat Rev Neurol2017; 13: 755–763.
148.
EltobgyMOweiraHPetrauschU, et al. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: A systematic review. Expert Rev Neurother2017; 17(7): 725–736.
149.
JohnsonDBReynoldsKLSullivanRJ, et al. Immune checkpoint inhibitor toxicities: Systems-based approaches to improve patient care and research. Lancet Oncol2020; 21(8): e398–e404.
DalakasMC. Neurological complications of immune checkpoint inhibitors: What happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord2018; 11: 1756286418799864.
152.
PiccaABerzeroGBihanK, et al. Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm2021; 8(3): e967.
153.
HemondCCBakshiRTauhidS, et al. Exacerbation of multiple sclerosis by BRAF/MEK treatment for malignant melanoma: The central vein sign to distinguish demyelinating lesions from metastases. J Investig Med High Impact Case Rep2021; 9: 23247096211033047.
154.
RotsteinDLSawickaKBharathaA, et al. CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler2020; 26(9): 1121–1124.
155.
Govind BabuKAttiliVSBapsyPP, et al. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol2007; 27(1): 43–44.
MassoudFIsmailIIAl-HashelJY, et al. CNS demyelination during tofacitinib therapy: First report. Mult Scler Relat Disord2020; 46: 102568.
158.
ErçobanRİslamoğluZGK. New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata. Dermatol Ther2022; 35(6): e15477.
159.
BelkaCBudachWKortmannRD, et al. Radiation induced CNS toxicity—Molecular and cellular mechanisms. Br J Cancer2001; 85: 1233–1239.
160.
BéhinADelattreJY. Complications of radiation therapy on the brain and spinal cord. Semin Neurol2004; 24(4): 405–417.
161.
LampertPTomMIRiderWD. Disseminated demyelination of the brain following Co60 (gamma) radiation. Arch Pathol1959; 68: 322–330.
162.
MotamedMRFereshtehnejadSMAbbasiM, et al. X-ray radiation and the risk of multiple sclerosis: Do the site and dose of exposure matter?Med J Islam Repub Iran2014; 28: 145.
163.
LandtblomAMFlodinUKarlssonM, et al. Multiple sclerosis and exposure to solvents, ionizing radiation and animals. Scand J Work Environ Health1993; 19(6): 399–404.
164.
KempSAllanRSPatanjaliN, et al. Neurological deficit following stereotactic radiosurgery for trigeminal neuralgia. J Clin Neurosci2016; 34: 229–231.
165.
GuilleminFBiauJCondeS, et al. Multiple sclerosis as differential diagnosis of radionecrosis for post-irradiation brain lesions: A case report. Clin Transl Radiat Oncol2020; 21: 44–48.
166.
EggersCKopatzVDörrW, et al. Localised multiple sclerosis-like disease after irradiation of the cervicothoracic spinal cord. Mult Scler Relat Disord2020; 45: 102443.
MadaniOBompaireFMokhtariK, et al. [Acute demyelination secondary to radiation therapy in a patient with glioma]. Presse Med2014; 43(10, Pt. 1): 1139–1143.
169.
LeonardiGCGainorJFAltanM, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol2018; 36: 1905–1912.
170.
GerdesLAHeldKBeltránE, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol2016; 80(2): 294–300.
171.
RomeoMALGarassinoMCMoiolaL, et al. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol2019; 266: 3163–3166.
172.
GettingsEJHackettCTScottTF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler2015; 21: 670.
173.
LuBYIsitanCMahajanA, et al. Intracranial complications from immune checkpoint therapy in a patient with NSCLC and multiple sclerosis: Case report. JTO Clin Res Rep2021; 2: 100183.
174.
GarciaCRJayswalRAdamsVAnthonyLBVillanoJL. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol2019;21:1336–1342.
175.
MontalbanXArnoldDLWeberMS, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med2019; 380: 2406–2417.
176.
MillerRCLachanceDHLucchinettiCF, et al. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys2006; 66: 1178–1186.
177.
YalachkovYDabanliDWengerKJ, et al. Concurrent CNS tumors and multiple sclerosis: Retrospective single-center cohort study and lessons for the clinical management. Neurol Sci2022; 43: 5513–5522.
178.
MurphyCBHashimotoSAGraebD, et al. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol2003; 60: 273–275.
179.
MilicMReesJH. Acute demyelination following radiotherapy for glioma: A cautionary tale. Pract Neurol2017; 17: 35–38.
180.
FilippiniGKrujaJDel GiovaneC. Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev2021; 11: CD013874.
181.
BrochetBDeloireMSPerezP, et al. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS ONE2017; 12: e0168834.
182.
HartungHPGonsetteRKonigN, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002; 360: 2018–2025.
183.
De StefanoNGiorgioABattagliniM, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler2018; 24: 222–226.
184.
MuraroPAMartinRMancardiGL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol2017; 13: 391–405.
185.
Le PageELerayETaurinG, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry2008; 79: 52–56.
186.
MuraroPAPasquiniMAtkinsHL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol2017; 74: 459–469.
187.
CollonguesNPatte-MensahCDe SezeJ, et al. Testosterone and estrogen in multiple sclerosis: From pathophysiology to therapeutics. Expert Rev Neurother2018; 18(6): 515–522.
188.
BehjatiSFrankMH. The effects of tamoxifen on immunity. Curr Med Chem2009; 16(24): 3076–3080.
189.
MichelLFoucherYVukusicS, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry2012; 83(8): 796–802.
190.
MainguyMTillautHDegremontA, et al. Assessing the risk of relapse requiring corticosteroids after in vitro fertilization in women with multiple sclerosis. Neurology2022; 99: e1916–e1925.
191.
YennurajalingamSFrisbee-HumeSPalmerJL, et al. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol2013; 31: 3076–3082.
192.
RykenTCMcDermottMRobinsonPD, et al. The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol2010; 96(1): 103–114.
193.
PaulsenOKlepstadPRoslandJH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial. J Clin Oncol2014; 32: 3221–3228.
194.
LinRJAdelmanRDMehtaSS. Dyspnea in palliative care: Expanding the role of corticosteroids. J Palliat Med2012; 15: 834–837.
195.
Ben-AharonIGafter-GviliAPaulM, et al. Interventions for alleviating cancer-related dyspnea: A systematic review. J Clin Oncol2008; 26: 2396–2404.
196.
LibertCDejagerL. How steroids steer T cells. Cell Rep2014; 7: 938–939.
197.
ArbourKCMezquitaLLongN, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol2018; 36: 2872–2878.
198.
ChassetFPagesCBiardL, et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: Negative impact of baseline corticosteroids. Eur J Dermatol2015; 25: 36–44.
199.
MargolinKErnstoffMSHamidO, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol2012; 13: 459–465.
200.
RicciutiBDahlbergSEAdeniA, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol2019; 37: 1927–1934.
201.
ScottSCPennellNA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol2018; 13: 1771–1775.
202.
DowneySGKlapperJASmithFO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res2007; 13: 6681–6688.
203.
HorvatTZAdelNGDangTO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol2015; 33: 3193–3198.
204.
WeberJLarkinJSchadendorfD, et al. Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). J Clin Oncol2017; 35: 9523–9523.
205.
IezzoniLIMcCarthyEPDavisRB, et al. Mobility impairments and use of screening and preventive services. Am J Public Health2000; 90: 955–961.
206.
ChevarleyFMThierryJMGillCJ, et al. Health, preventive health care, and health care access among women with disabilities in the 1994-1995 National Health Interview Survey, Supplement on Disability. Womens Health Issues2006; 16: 297–312.
207.
ToddAStuifbergenA. Barriers and facilitators to breast cancer screening: A qualitative study of women with multiple sclerosis. Int J MS Care2011; 13: 49–56.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
